Study of SHR-A1921 or SHR-A2009 for previously treated advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests two new drugs (SHR-A1921 and SHR-A2009) for people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after previous treatments, including antibody-drug conjugate therapy. The goal is to see if these drugs can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
- Your cancer has grown or not responded after standard treatments, including antibody-drug conjugate therapy.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG score 0 or 1).
- You have adequate organ function and are willing to use contraception or abstain from sex during the study and for 180 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests an investigational drug called SHR-A1811 in people with non-small cell lung cancer that has spread or cannot be removed by surgery and has a HER2 alteration. The goal is to see if the drug is effective and safe for this type of cancer.
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.